A Safety and Efficacy Clinical Study to Evaluate the Narrowing of the Aorto-iliac Arteries While Using Gadodiamide

Arterial Occlusive Diseases Clinical Trial

Official title:

A Multicentre, Phase 3, Open-Label Study to Assess the Efficacy and Safety of 0.1 mmol/kg Omniscan (Gadodiamide Injection) for Magnetic Resonance Angiography (MRA) of the Aorto-iliac Arteries

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00209443
• Other study ID #: SOV302
• Status: Completed
• Phase: Phase 3
• Start date: September 2004
• Est. completion date: February 28, 2006

Study information

• Verified date: April 2019
• Source: GE Healthcare
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Magnetic Resonance Angiography (MRA) is an examination similar to Magnetic Resonance Imaging (MRI) which uses a magnetic field and a contrast medium when needed to visualize blood flow in the arterial vessels throughout the body.

Gadodiamide, a contrast medium, is already approved and is used to image blood vessels by directly injecting it into the vein, but this procedure has not been formally tested to image the aorto-iliac vessels using MR.

The study is designed to determine the presence or absence of a relevant stenosis (ie greater than/equal to 50%) or occlusion in aorto-iliac arteries. Intra-arterial Digital Subtraction Angiography (IADSA) will be used as the standard of truth.

Description:

GEHC has decided not to provide this detail

Recruitment information / eligibility

• Status: Completed
• Enrollment: 407
• Est. completion date: February 28, 2006
• Est. primary completion date: February 28, 2006
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Study subjects must be adults with confirmed or suspected aorto-iliac stenosis.

• The subject must have been referred for Digital Subtraction Angiography.

Exclusion Criteria:

• The subject has a known hypersensitivity to either conventional X-ray or gadolinium based MR contrast media including, but not restricted to, the investigational product.

• The subject is lactating.

• The subject is pregnant as defined by a serum or urine beta-HCG pregnancy test obtained within 24 hours before administration of the investigational product.

• The subject received or is scheduled to receive MRI contrast medium within 24 hours prior to or less than 24 hours after administration of the investigational product.

• The subject received or is scheduled to receive X-ray contrast medium within 24 hours prior to or less than 24 hours after administration of the investigational product.

• The subject received an investigational product other than OMNISCAN (gadodiamide) within 30 days prior to OMNISCAN administration or will receive an investigational product within the follow-up period proposed for this study.

• The subject presents any clinically active, serious, life-threatening disease with a life expectancy of less than 6 months.

• The subject has a serum creatinine value of >= 3.5 mg/dL (309.4 µmol/L).

• The subject has previously been included in this study.

• The subject has a contra-indication for MRI according to accepted clinical guidelines.

• The subject has metal implants and/or stents in the aorto-iliac region and/or hip replacement.

Related Conditions & MeSH terms

• Aorto-iliac Stenosis
• Arterial Occlusive Diseases

Intervention

Drug:
• Gadodiamide Injection

Locations

Country	Name	City	State
Germany	Amersham Buchler GmbH & Co. KG	Ismaning

Sponsors (1)

Lead Sponsor	Collaborator
GE Healthcare

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Differences in subject level and vessel level sensitivity and specificity between CE-MRA and TOF-MRA in detecting stenosis,(>50% occlusion) in aorto-iliac arteries. IA-DSA is the truth standard.		27 hours
Secondary	Differences in sensitivity, specificity, accuracy, PPV and NPV at subject and/or vessel level between CE-MRA and TOF-MRA in detecting stenosis (50% occlusion) in aorta-iliac arteries; Revascularisation strategies based on CE-MRA, TOF-MRA and IA DSA		27 hours